Skip to content
Screener

Operating Cash Flow at other companies

Eli Lilly logo
Eli LillyLLY
$10.69B+246%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$3.18M+2,565%
Altimmune logo
AltimmuneALT
-$20.94M-24.4%
Viking Therapeutics logo
Viking TherapeuticsVKTX
-$113.98M-118%
Wave Life Sciences logo
Wave Life SciencesWVE
-$53.58M-16.5%
Arrowhead Research logo
Arrowhead ResearchARWR
$84.44M-81.6%

Other financials

Income statement

See full
Revenue$364.3M+71.2%
Gross profit$43.5M
Operating income-$56.3M-19.3%
Net income-$57.9M-37.0%
EPS (diluted)-$1.99-4.7%

Balance sheet

See full
Cash & equivalents$292.9M+53.2%
Total debt$377.9M+179%
Total equity$523.7M-24.7%
Total assets$1.2B+22.6%

Cash flow

See full
CapEx$4.3M
Free cash flow-$171.3M-92.7%

Valuation

See full
Market cap$11.88B+57.6%
Enterprise value$11.96B+59.9%
P/S9.3×-5.4×

Profitability

See full
Gross margin96.5%
Operating margin-25.1%-9.2pp
Net margin-25.3%-8.8pp
FCF margin-59.8%-29.6pp

Returns & leverage

See full
Return on equity-53.3%+47.0pp
Debt / equity0.7×+0.5×
Current ratio3.2×-1.9×

Where this comes from

Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The source filing: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 9:04 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-030947
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Accounts payable3,584(1,543)
Accrued liabilities4,287(530)
Accrued interest, net of interest received on maturity of investments1,9802,853
Net cash used in operating activities(167,435)(88,891)
Cash flows from investing activities:
Purchases of marketable securities(157,829)(130,812)
Sales and maturities of marketable securities353,869294,690
Purchases of property and equipment, net of disposals(3,849)

Item 1. Financial Statements (Unaudited):

FAQ

What is Madrigal Pharmaceuticals, Inc.'s operating cash flow?
Madrigal Pharmaceuticals, Inc. (MDGL) reported operating cash flow of -$167.44M in Q1 2026.
How has Madrigal Pharmaceuticals, Inc.'s operating cash flow changed year-over-year?
Madrigal Pharmaceuticals, Inc.'s operating cash flow decreased by 88.4% year-over-year, from -$88.89M to -$167.44M.
What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s operating cash flow?
Over 3 years (2021 to 2024), Madrigal Pharmaceuticals, Inc.'s operating cash flow has grown at a 35.3% compound annual growth rate (CAGR), from -$183.92M to -$455.57M.
What does operating cash flow mean?
Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.

Ask your AI about Madrigal Pharmaceuticals, Inc.'s operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude